Who
Andrea Corcoran
Officer
Company insider
Files Form 4 as: Officer, Atea Pharmaceuticals; Exec. VP, Legal and Admin., Idenix Pharmaceuticals.
In numbers
- Trades disclosed
- 32
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $61K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 7 Mar 2006
- Last trade
- 11 Mar 2026
- Last filed
- 13 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Mar 2026filed 13 Mar 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $74K60,000 at $1.24 | filing |
| 11 Mar 2026filed 13 Mar 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —60,000 at $0.00 | filing |
| 11 Mar 2026filed 13 Mar 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —60,000 at $0.00 | filing |
| 11 Mar 2026filed 13 Mar 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $74K60,000 at $1.24 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —54,866 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $68K16,104 at $4.24 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —44,366 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —44,366 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,500 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —180,000 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,500 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —180,000 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —54,866 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $68K16,104 at $4.24 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —44,367 at $0.00 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,500 at $0.00 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —44,367 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —10,500 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $49K16,102 at $3.06 | filing |
News
No headline names them, or the companies they trade most, lately.